Clinuvel Pharmaceuticals Limited (CUV.XA)
Cboe AU - Cboe AU Real Time Price. Currency in AUD
Add to watchlist
At close: 03:59PM AEST
| Previous Close | 14.95 |
| Open | 14.99 |
| Bid | 14.95 x N/A |
| Ask | 15.10 x N/A |
| Day's Range | 14.94 - 15.06 |
| 52 Week Range | 12.98 - 21.43 |
| Volume | |
| Avg. Volume | 20,341 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | 31.99 |
| EPS (TTM) | 0.47 |
| Earnings Date | Feb 22, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...
GlobeNewswirePhotomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years
- Simply Wall St.
Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Clinuvel Pharmaceuticals...
© 2024 Yahoo. All rights reserved.